Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Owning CSL Ltd (ASX: CSL) shares over the past decade has been very rewarding, with good dividend growth and enormous capital growth. As shown on the chart below, the CSL share price has soared more than 200% in the past decade.

In my view, CSL may be the most impressive business on the ASX, with a market capitalisation of $100 billion. Its growth and global success are commendable.

Long-term shareholders are receiving much bigger dividends and are predicted to see even larger payments.

Let's have a look at how the CSL dividend could grow between now and the 2029 financial year.

Man holding Australian dollar notes, symbolising dividends.

Image source: Getty Images

This year, FY25

We're already close to halfway through the CSL 2025 financial year, so it won't be long before shareholders learn the FY25 interim dividend payment with the half-year result, which is expected in February 2025.

As for the annual dividend per share, UBS is currently forecasting that the CSL dividend could jump by 12% to US$2.96 per share. At the current CSL share price, that would represent a dividend yield of close to 1.7%.

UBS also considers the "possibility of a less vaccine-friendly US administration", which could impact CSL's vaccine business.

Next year, FY26

In the 2026 financial year, UBS is expecting CSL's profit to rise by more than 10%, and this can help the company's dividend rise too.

UBS is projecting that the CSL dividend could jump by another 12% to US$3.31 per share. That would represent a dividend yield of close to 1.9%. Not huge, but it's growing at a good pace.

After that, FY27

The 2027 financial year could see the business continue to grow its profit and dividend at a pleasing double-digit speed.

UBS projects that owners of CSL shares could receive an annual dividend per share of US$3.71, an increase of 12%. At the current valuation, that would represent a dividend yield of 2.1%.

Then, FY28

As an ASX healthcare share, it's quite possible that the company could deliver consistent profit growth over this period of time.

According to UBS, in the 2028 financial year, CSL could deliver a dividend increase of close to 12%, taking the annual payment to US$4.15. At the current CSL share price, that would represent a dividend yield of 2.35%.

Finally, FY29

The 2029 financial year is projected to be the best year of all – it could see yet another double-digit increase in percentage terms of both profit and dividend.

UBS forecasts that CSL's dividend could increase by another 12% in FY29 to US$4.65. At the current valuation, this payout would mean a dividend yield of 2.6%.

A 2.6% dividend yield isn't huge, but it shows how the dividend could scale upwards. Rising profit could also be exactly what investors want to see with CSL shares.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 reasons to buy Pro Medicus shares today

Two leading investment analysts believe Pro Medicus shares are primed for a rebound.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Healthcare Shares

Should I invest $10,000 into CSL shares? Yes or no

Is it time to pick up this fallen giant? Let's dig deeper into things.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »